Uses of Ebrasun

This is an automatically translated article.

Ebrasun is often prescribed by doctors in the treatment of the larvae of the filariasis Onchocerca volvulus. The drug is used for adults and children from 15kg and over. The following article provides you with information about the uses and precautions when using Ebrasun.

1. What is the use of Ebrasun for gfi?

Ebrasun is an anti-helminthic drug with the main ingredient Ivermectin, which is prepared in the form of tablets with a content of 6mg.
Ivermectin is a semi-synthetic derivative of one of the avermectins, a group of substances with a large cyclic lactone structure, isolated from the fermentation of Streptomyces avermitilis.
Ivermectin has a therapeutic effect on roundworms such as roundworms, strongyloides, pinworms, hookworms, roundworms and filariasis Wuchereria bancrofti. However, Ivermectin has no effect on tapeworms and liver flukes. The drug Ivermectin is effective against Onchocerca volvulus larvae, reducing the number of filariasis larvae. Ivermectin is also effective against the larvae of filariasis in the lymphatic vessels, the drug is used to treat the community in endemic areas. After treatment, it must be repeated at an interval of at least 3 months. In community treatment, the dose is given annually or every 6 months.
Currently, Ivermectin is the treatment of choice in the filariasis Onchocerca volvulus. The drug is very effective against filariasis, but Ivermectin has little effect on adult parasites. Larvae of filariasis in the skin disappear rapidly after taking 2-3 days, but the larvae in the cornea and anterior chamber of the eye take longer. The maximum effect of Ivermectin in the treatment of filariasis Onchocerca is about 3 - 6 months, in the treatment of strongyloidiasis is 3 months.
The effects of Ivermectin can last up to 12 months. After taking the drug for about a month, the larvae in the uterus of the adult filariasis cannot escape, degenerate and die. The prolonged effect of the drug on the larvae is useful in stopping the transmission of the disease.
Mechanism of action: Ivermectin binds selectively and strongly to the chloride ion channel glutamate found in nerve and muscle cells of invertebrates. This leads to increased permeability of the cell membrane to chloride ions and negative membrane potential of this cell leading to paralysis and death of the parasite.
Indications:
Ebrasun is used for adults and children weighing 15kg or more: treatment of Onchocerca filariasis caused by Onchocerca volvulus larvae, treatment of intestinal strongyloidiasis. Ebrasun is contraindicated for use in the following cases:
Hypersensitivity to Ivermectin or any other ingredient in Ebrasun. Do not use Ebrasun in the treatment of Loa Loa filariasis due to the potential for neurotoxicity (encephalopathy). Patients with diseases associated with blood-brain barrier disorders, such as meningitis and African trypanosoma.

2. How to take Ebrasun

Ebrasun tablets taken with water on an empty stomach, avoid eating within 2 hours before and after taking the drug. Dosage of Ebrasun for adults, children ≥ 15kg and > 5 years old:
Onchocerca filariasis: Single dose 0.15mg/kg. Using higher doses will increase undesirable effects without increasing the effectiveness of treatment. It is necessary to re-treat at the same dose every 3-12 months until the symptoms are gone and to be sure that the larvae of Onchocerca are not controlled.
In case the patient has a larval infection in the eye, it is necessary to re-treat more often, maybe every 6 months to use the drug again.
Below is the recommended dose of Ivermectin based on body weight in the treatment of Onchocerca filariasis: the prescribed dose is 0.15mg/kg.

Overdosage of Ebrasun and treatment:
Symptoms of Ebrasun intoxication: headache, dizziness, dizziness, weakness, skin rash, edema, nausea, vomiting, diarrhea. Other adverse effects include seizures, ataxia, abdominal pain, dyspnea, paresthesia and urticaria. Treatment: when using an overdose of Ebrasun, it is necessary to infuse fluids and electrolytes, support breathing, use antihypertensive drugs if the patient develops hypotension. Induce vomiting or gastric lavage as soon as possible in case of overdose. After that, bleach and other antitoxic measures can be applied to prevent further absorption of Ivermectin into the body.

3. Undesirable effects when using Ebrasun

Ivermectin is a safe drug, most of the undesirable effects of the drug are due to the immune response to the dead larvae. Therefore, the severity of undesirable effects when using Ebrasun is related to the density of larvae in the skin.
Undesirable effects that have been reported with Ivermectin include fever, itching, dizziness, lightheadedness, edema, sweating, shivering, skin rash, enlarged and painful lymph nodes, joint swelling, pain muscles, facial swelling, cough, sore throat, headache. Severe orthostatic hypotension has been associated with tachycardia, sweating, and confusion. Ivermectin may cause moderate eye irritation. Increased liver enzymes and eosinophilia have been reported. Adverse effects usually occur in the first 3 days after treatment, depending on the dose of Ivermectin. The proportion of reported ADRs varies widely.
Ivermectin can cause skin reactions and systemic reactions, ocular reactions of varying degrees in patients with Onchocerca filariasis. These reactions may be the result of an allergic and inflammatory response to the death of the filariasis larvae. Manage these reactions with antihistamines, pain relievers, or corticosteroid injections at the onset of symptoms.
Ivermectin does not kill adult Onchocerca filariasis, so regular monitoring and re-treatment is required.

4. Note when using Ebrasun

There have been reports of severe encephalopathy or death in patients following the use of Ivermectin for the treatment of Onchocerca infections in endemic areas (due to the presence of larvae in the blood). Because the safety and efficacy of ivermectin use in children weighing <15 kg has not been established, Ebrasun should not be used in children weighing < 15 kg and < 2 years of age, because the blood-brain barrier may be possible. still underdeveloped. In community treatment, do not use drugs for pregnant women, children <15kg and seriously ill people. Ivermectin booster therapy in immunocompromised patients. Because Ivermectin may increase GABA, it has been suggested that the drug has a nervous system effect in patients with a compromised blood-brain barrier (meningoencephalitis, Trypanosoma disease). Patients with Onchocerca filariasis using Ivermectin may experience increased reactions, more severe adverse reactions, especially edema and worsening of the disease. Pregnancy: A teratogenic effect has been observed with Ivermectin in animal studies. Because there are no adequately controlled studies in pregnant women, Ebrasun is not recommended for use in pregnant women. Lactation: Ivermectin is excreted in human milk at low concentrations (<2% of the administered dose). The safety of Ivermectin in the neonate has not been established, therefore Ebrasun should be administered to the mother only when the benefit to the mother outweighs the risk to the infant. The drug should not be given to the mother until the baby is at least 1 week old.

5. Drug interactions

Theoretically, Ivermectin might potentiate the effects of GABA receptor agonists (sodium valproate, benzodiazepines). Vitamin K antagonists: Ivermectin may increase the effects of this drug when used concurrently. Azithromycin: increases the effect of Ivermectin. Ivermectin reduces the effect of BCG, typhoid vaccine. Therefore, avoid co-administration of Ebrasun with these vaccines. Ebrasun is often indicated in the treatment of larvae of Onchocerca volvulus but has no effect on adult filariasis. Before taking Ebrasun, it is best to consult your doctor for instructions on safe and effective use of the drug.